(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
Signature Scents: A Manual for Outstanding Fragrances- Instructions to Pick the Ideal Pre-assembled Home for Your Necessities
- Top 10 Smash hit Computer games of the Year
- A volcanic eruption may have catalyzed the plague's arrival in Europe, study suggests
- The Best Web-based Courses for Expertise Improvement
- The most effective method to Stay away from Normal Traps While Recruiting a Material Organization
- WHO issues guidance on GLP-1 drugs for obesity
- Financial plan Cordial Home Redesigns That Add Worth
- Building an Individual Brand: Illustrations from Powerhouses
